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Alzheimer’s disease (AD) is a common neurodegenerative disease characterized clinically by progressive
deterioration of memory, and pathologically by histopathological changes including extracellular deposits of
amyloid-beta (A-beta) peptides forming senile plaques (SP) and the intracellular neurofibrillary tangles (NFT) of
hyperphosphorylated tau in the brain. This review focused on the new developments of amyloid cascade
hypothesis with details on the production, metabolism and clearance of A-beta, and the key roles of some
important A-beta-related genes in the pathological processes of AD. The most recent research advances in
genetics, neuropathology and pathogenesis of the disease were also discussed.
Keywords: Alzheimer’s disease, A-beta, APP, BACE1, Presenilins, ApoE, Neprilysin/insulin-degrading enzymeReview
Introduction
Alzheimer’s disease (AD) was originally described by
Alois Alzheimer in 1906 and was renamed several years
later by Emil Kraepelin [1]. AD is characterized clinically
by progressive deterioration of memory, and pathologic-
ally by histopathological changes including extracellular
deposits of amyloid-β (Aβ) peptides forming senile pla-
ques (SP) and the intracellular neurofibrillary tangles
(NFT) of hyperphosphorylated tau in the brain, which
are commonly regarded as the hallmarks of the disease.
Epidemiological studies have shown that AD is the
leading cause of dementia, accounting for about 50% of
all cases worldwide [2]. Aging is the most obvious risk
factor for developing AD. It was estimated that the age-
associated prevalence rate of AD would be doubled every
5 years in the patients beyond 65 years of age [3]. In
addition to aging, several other possible biological (such
as genetic alterations and polymorphisms, and abnormal
immune or inflammatory responses) and environmental
factors (such as education, traumatic injury, oxidative* Correspondence: zzhao@brain.ecnu.edu.cn
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reproduction in any medium, provided the orstress, drugs, and hormone replacement) and the interac-
tions among these factors have been considered to be
contributors to a common pathway leading to AD [4,5].
Despite the remarkable improvements in our under-
standing of the pathogenesis of the disease have been
made over last several decades, the accurate mechanism
of AD remains unclear. Several independent hypotheses
have been proposed to address the pathological lesions
and neuronal cytopathology in connection with apolipo-
protein E (ApoE) genotyping, hyperphosphorylation of
cytoskeletal proteins, oxidative stress, abnormal cell
cycle re-entry, inflammation and Aβ metabolism. The
amyloid metabolic cascade and the posttranslational
modification of tau protein are considered to be the most
important hypotheses in AD, although none of them or
other theories alone is sufficient to explain the diversity of
biochemical and pathological abnormalities of AD, which
is believed to involve a multitude of cellular and biochem-
ical changes [3]. According to amyloid cascade hypothesis
[6,7], accumulation of extracellular senile plaques made
primarily by deposits of Aβ peptide is thought to be one
of the most prominent pathogenenic mechanisms of AD.
Although the direct causal link between Aβ and impaired
neuronal function and memory is still under elucidation,
it is undoubted that Aβ plays a critical role in the neuro-
pathology of AD. This review focuses on the newLtd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly cited.
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vance to the most recent research advances in the genet-
ics, neuropathology and pathogenesis of AD. In the
following sections, the recent progress of the studies on
genes (see Figure 1) identified to be involved in the pro-
duction, deposition and degradation of Aβ, the possible
contributions of different Aβ assemblies to AD, and their
pathological functions are reviewed.
Aβ-related genes
Amyloid precursor protein (APP)
APP is an integral membrane glycoprotein expressed in
the brain and central nervous system (CNS). It can
undergo sequential proteolytic processing by twoFigure 1 Aβ and Aβ-related genes in AD. Aβ is produced by sequential
a multi-protein complex, of which PS1 or PS2 is the catalytic core. After be
isoforms of ApoE. These Aβ-binding ApoE isoforms will allow Aβ to underg
degradation by Aβ-degradating enzymes (IDE or neprilysin), deposition or
of ApoE2 or ApoE3. While ApoE2 and ApoE3 help Aβ to be cleared by tran
implicating it to be a high risk factor for AD. There is a feedback existing in
released, which is translocated into the nucleus and initiates the transcripti
hereby reduces Aβ to a proper level.pathways: the α pathway and the β pathway. In most
cases, APP is sequentially cleaved via α pathway by α-
secretase and γ-secretase. The α-secretase cleavage of
APP is non-amyloidogentic, whereas the β pathway leads
to Aβ generation. In the β pathway APP is initially
cleaved by β-secretase to release sAPPβ into extracellu-
lar space and leave the 99-amino-acids C-terminal frag-
ment (C99) within the membrane. C99 is subsequently
processed to 38-43 amino acids by γ-secretase to release
Aβ and APP intracellular C-terminal domain (AICD)
[8]. In most cases, the γ-cleavage produces Aβ40, while
it could also generate a more toxic variant, Aβ42. It
has been recently found that γ-secretase activity for
Aβ production could be also negatively regulated bycleavage of APP by β-secretase (BACE1) and γ-secretase. γ-secretase is
ing produced, Aβ is secreted outside the cell and binds to various
o metabolism in different pathways, e.g., clearance via BBB,
trafficking into the cell. The affinity of ApoE4 to Aβ is lower than that
sport or degradation, ApoE4 mainly induce Aβ to aggregation,
vivo to keep proper Aβ levels. When Aβ is generated, AICD is
on of neprilysin. Increased neprilysin protein will degradate Aβ and
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way and the β pathway [9].
Physiological functions
Although APP has been implicated in the pathology
of AD, much evidence shows that APP has its own
physiological functions, especially in regulation of synap-
tic function and neuronal activity. Mice lacking APP
and APP-like protein 2 show deficits in structure and
function in neuromuscular synapses [10]. In cultured
hippocampal neurons, lack of APP also affects synapse
formation and transmission [11]. On the contrary, mice
overexpressing APP exhibit enhanced synaptic plasticity
and spatial memory [12]. Kamenetz et al found that
APP processing could have a normal negative feed-back
function in modulating Aβ levels to maintain proper
neuronal activity [13]. In addition, APP processing also
regulates cholesterol metabolism. When Aβ is produced,
AICD is stabilized by Fe65, localized to the nucleus and
binds to transcription factor Tip60. The protein-protein
interaction initiates the transcription of the Aβ degrad-
ation enzyme, neprilysin, thus reduces the Aβ levels
[14]. AICD-Fe65-Tip60 complex has been shown to sup-
press the transcription of lipoprotein receptor LRP1,
which is known to regulate ApoE and cholesterol levels
in CNS, suggesting a biological interaction between APP
and ApoE/cholesterol metabolisms [15]. Furthermore,
APP possesses the biological function in controlling
cholesterol biosynthesis and sphingomyelin production
via Aβ-dependent modulation of neuronal levels of
Hydroxymethylglutaryl-CoA reductase (HMGR) and
sphingomyelinases (SMases), indicating a functional
basis of APP processing for the link between lipids and
AD [16]. Endogenous AICD in primary neurons is tem-
porally up-regulated during neuronal differentiation, and
such a physiological function is negatively mediated by
neuron-specific c-Jun N-terminal kinase JNK3 via phos-
phorylation of APP [17]. APP and its mammalian para-
logs, the amyloid precursor-like proteins 1 and 2, have
been demonstrated to be capable of forming homo- and
hetero-complexes that exhibit physiological function in
promoting trans-cellular adhesion in vivo [18]. Han et al
also characterized a neuroprotective function of APP in
preventing tau hyperphosphorylation via suppressing
overactivation of Cdk5 (Cyclin-dependent kinase 5) [19].
Pathological functions
It is well known that the pathologcial function of APP
lies on its amyloidogenic processing. It has been recog-
nized that many APP mutations cause autosomal domin-
ant early-onset AD. Increasing of gene copy number
including genomic duplication in the APP locus [20,21]
may also lead to AD dementia in earlier life. Interest-
ingly, a recently identified mutation adjacent to β-site(A673T) of APP gene was shown to result in Aβ reduc-
tion and protection against cognitive decline in the eld-
erly without AD [22]. On the other hand, however,
overexpression of FAD-linked mutant APP could lead to
olfactory sensory neuron apoptosis in the absence of
amyloid plaque, which might be the mechanism of defi-
cits in odor detection, one of the earliest AD symptoms
[23]. All these indicate that both APP genomic duplica-
tion and mutations can lead to changes in APP function
and subsequent Aβ metabolism, strongly implicating a
central role of not only APP but also its β-cleavage in
pathogenesis of AD. To identify the pathological func-
tions of APP, many APP transgenic mice including wild-
type human APP and FAD-linked APP mutations have
been generated. FAD-linked APP mutation mice show
an increase in the amount, length, and fibrillogenic gen-
eration of Aβ species and have amyloid deposits at the
age of 18 months [24] while, surprisingly, mice overex-
pressing APP do not develop AD pathologies or memory
deficits but instead exhibit enhanced spatial memory,
which depends on the function of AICD generated by β-
secretase-mediated cleavage [12]. Studies on APP muta-
tion transgenic mice have given us much information of
AD pathogenesis, but the molecular mechanisms still
need further investigation.
Beta-site APP cleaving enzyme 1 (BACE1)
BACE1 is known as the major β-secretase to cleave APP
at β-site to produce β-CTF for Aβ generation in neurons
[25]. BACE1 and its homolog, BACE2, have different
transcriptional regulations and functions. BACE1 knock-
out mice are almost normal without Aβ generation [26],
and BACE1 deficits can rescue the memory impairment
and cholinergic dysfunction in mutant human APP
transgenic mice [27]. Repetto et al demonstrated that
overexpression of BACE1 in H4 human cells can regu-
late APP intracellular signaling by interaction with the
ShcA adaptor protein [28]. BACE1-mediated β-cleavage
has been showed to be physiologically modulated by dif-
ferent spliced transcripts [29] and the activation of pro-
tein kinase C [30]. Impaired intracellular calcium
homeostasis may stimulate BACE1 gene expression via
nuclear factor of activated T cells 1 (NFAT 1) signaling
pathway, leading to accelerated production of Aβ [31].
BACE1 could be modulated by Aβ42, but not Aβ40, via
an NFκB-dependent signaling pathway [32], and Aβ42-
positive plaques could increase BACE1 levels in sur-
rounding neurons before neuron loss occurs [33]. Aβ42
could also induce expression of BACE1-antisense tran-
script, a natural regulator of BACE1 expression, which
increased BACE1 mRNA stability [34]. Thus, increased
BACE1 levels might be a positive feedback for Aβ42 to
initiate the amyloidogenesis of AD. In addition, BACE1-
dependent cleavage of low density lipoprotein receptor-
Dong et al. Translational Neurodegeneration 2012, 1:18 Page 4 of 12
http://www.translationalneurodegeneration.com/content/1/1/18related protein (LRP) can mediate the endocytosis of
APP and ApoE [35] and has been suggested to be
involved in the pathology of AD.
Presenilin (PS) 1 and 2
PS is an eight membrane-spanning protein with an N-
terminus, a ‘loop’ domain between transmembrane (TM)
domain six and seven, and a C-terminus that is oriented
toward the cytoplasm. Aspartate residues at position
D275 (in TM6) and D385 (in TM7) are critical for PS
function [36]. There are two PS genes: PS1 and PS2. PS,
nicastrin, aph-1, and pen-2 form the active γ-secretase
complex while PS is the catalytic core of the complex
[37]. γ-secretase cleaves not only APP but many other
type I transmembrane proteins (such as Notch, cadher-
ins and LRP) as well [38], strongly implicating PS in
both AD pathogenesis and many other neuronal physio-
logical activities including development, calcium homeo-
stasis and apoptosis.
PS gain of function
PS1 mutations are the most common genetic cause for
early-onset familial AD (FAD). PS genes harbor about
90% of identified FAD mutations. There have been more
than 100 PS1 mutations being described. Some of them,
such as L85P, P117L, P117S, insF1, and L166P, are asso-
ciated with very early onset (usually before age of 30
years old) of cognitive decline [39]. Many of the PS1
mutations lead to an increase in relative production
of more toxic Aβ42 peptides. The prevailing amyloid
hypothesis posits that deposits of Aβ peptides, especially
the more hydrophobic and aggregation-prone Aβ42,
initiates a pathogenic cascade, leading to neurodegenera-
tion in AD [40]. This has been referred to as the toxic
gains-of-function of PS in triggering neurodegeneration
in AD. The amyloid cascade hypothesis is supported by
the results from FAD-linked mutant transgenic mice.
PS1 mutation significantly accelerates the rate of Aβ
deposition in mutant APP transgenic mice [24]. Expres-
sion of human mutant PS1 in PS1 null mice is sufficient
to elevate Aβ1-42, supporting a gain-of-function activity
of PS1 mutation [41].
PS loss of function
However, the most recent evidence from several inde-
pendent PS transgenic model-based studies emerged
that supports the “PS loss of function” hypothesis as a
potential pathogenic mechanism of AD. Firstly, mice
lacking both PSs in the forebrain show AD-like progres-
sive neurodegenerative phenotypes including forebrain
degeneration, impaired synaptic plasticity and spatial
memory without Aβ production [42-46]. A number of
PS1 mutations (L113P, G183V and insR352) have been
found in patients with familial forms of frontotemporaldementia (FTD), a common neurodegenerative dementia
that lacks amyloidogenesis [47-49]. These observations
suggest that neurodegeneration can take place in the
absence of Aβ.
PS genes have been identified to play an important
role in many normal physiological activities. These
physiological functions can be classified to γ-secretase-
dependent and -independent functions. There are many
identified γ-secretase substrates. By cleavage of these
substrates, PSs mediate their multiple functions in devel-
opment, calcium homeostasis, cell adhesion, transport,
trafficking/localization, and apoptosis [36,38,50]. FAD-
linked PS mutations might impair the γ-secretase-
dependent proteolysis of some of the substrates, such as
Notch, N-cadherin and tyrosinase, resulting in loss
of the related functions of PS [51,52]. Meanwhile,
FAD-linked PS mutations might also impair some
γ-secretase-independent functions, such as the regula-
tion of β-catenin-dependent signaling [53], modulation
of phosphatidylinositol 4,5-bisphosphate metabolism
[54], endoplasmic reticulum [Ca2+] leak function [55],
PI3K/Akt signaling pathway-dependent neuroprotective
roles [56], synaptic homeostasis [57] and fast axonal
transport of APP [58]. In addition to involving in Aβ
generation, PS genes participate in the regulation of Aβ
degradation mediated by AICD-dependent transcrip-
tional modulation of the degrading enzyme, neprilysin
[14]. FAD-linked PS mutations may disrupt the physio-
logical function of PSs in regulating Aβ levels.
Surprisingly, many γ-secretase inhibitors at low con-
centration enhance Aβ42 production while reducing
Aβ40 levels, similar to the effects of FAD-linked PS
mutations [59-61], suggesting that PS mutation could re-
sult in a partial loss of its function. Furthermore, PS
mutations are scattered throughout the protein’s N-
terminus, C-terminus and transmembrane domains, oc-
curring at about 20% of the amino acid residues. As it is
impossible for different PS mutations to gain the same
toxic function, it is therefore most likely that the loss of
normal PS function by ‘random’ changes of amino acid
residues is the culprit for triggering AD pathogenesis.
However, the “PS loss of function” hypothesis is still un-
able to explain the exact mechanism for FAD-linked
APP mutations that cause AD. In this regard, it has been
assumed that Aβ42 might act as an inhibitor of γ-secre-
tase. APP mutations may interfere with the physiological
roles of PS and hereby initiate the pathogenic cascades
of AD [51]. Further investigations are required to con-
firm the hypothesis.
Apolipoprotein E (ApoE) and other apolipoproteins
Apolipoproteins play important roles in regulating Aβ
pathology. ApoE is the predominant apolipoprotein in
the CNS and is synthesized and secreted mainly by
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in transporting lipids among CNS cells to keep lipid
homeostasis, repairing injured neurons, maintaining syn-
aptic connections, and scavenging toxins. ApoE gene
encodes three alleles: ApoE2, ApoE3 and ApoE4. The
alleles differ only in two residues at sites 112 and 158.
ApoE3 has Cys-112 and Arg-158, ApoE4 has arginine
and ApoE2 cysteine at both sites. The differences
between the alleles determine their distinct functions.
ApoE2 is neuroprotective while ApoE4 is related to a
variety of diseases.
It has been recognized that ApoE4 is the major genetic
risk factor for sporadic AD. ApoE4 is associated with
cognitive deficits [64], and the effect of ApoE4 is moder-
ated by cholesterol levels [65]. In contrast to ApoE2 and
ApoE3, ApoE4 is more sensitive to stress or injury,
which causes neuron-specific proteolysis with the forma-
tion of a bioactive toxic C-terminal fragment [66].
Transgenic mice expressing high levels of carboxyl
terminal-cleaved product ApoE4 (272–299) in the brain
die 2–4 months after birth. The cortex and hippocampus
of the transgenic mice display AD-like neurodegenera-
tive alterations [67].
ApoE acts as the Aβ chaperone and binds to different
forms of Aβ, leading to changes in the structure, toxicity
and deposition of Aβ [68,69]. Pharmacological blocking
ApoE-Aβ interaction can significantly reduce the forma-
tion of amyloid plaques and attenuate the deficits of
memory in the transgenic mice carrying a Swedish
K670L/M671L APP mutation (APPSWE) or a K670L/
M671L APP plus a PS1 M146L mutation (APPSWE/PS1)
[70]. The effects of ApoE on Aβ depositions are sup-
ported by the observation that intake of sugar-sweetened
water induces amyloidosis and memory impairment and
increases ApoE levels in the brain of a transgenic mouse
model of AD [71]. Besides, it is recently demonstrated
that increased expression of ApoE by the retinoid X
receptors agonist results in enhanced clearance of sol-
uble Aβ and reduced Aβ plaque, and leads to reversal of
cognitive deficits and improvement of synaptic functions
in an AD mouse model [72]. Nevertheless, increasing
evidence suggests that the regulatory effect of ApoE on
Aβ deposition appears to be isoform-specific (ApoE4 >
ApoE3 > ApoE2) and gene dosage-related [73]. ApoE
promotes the proteolytic degradation of Aβ by modulat-
ing the activity of Aβ degrading enzyme, which depends
on ApoE isoform structure and the lipidation status
[69,74]. ApoE also participates in the regulation of Aβ
production through LRP pathway [75]. Given that APP
processing is dependent on membrane cholesterol levels
and that ApoE is the transporter of cholesterol [76],
ApoE might therefore be a important player in Aβ gen-
eration. In fact, it has been reported that activation of
the amyloid cascade may isoform-specifically inducelysosomal activation and neurodegeneration of hippo-
campal CA1, entorhinal and septal neurons, which are
responsible for the marked cognitive deficits in apolipo-
protein transgenic mice [77]. ApoE4-induced impair-
ments of neuroplasticity following environmental
stimulation are also found to be mediated by intraneuro-
nal oligomerized Aβ [78]. Furthermore, C-terminal frag-
ment of ApoE could induce tau phosphorylation in
neurons that represents another character in AD brain,
depending on both the isoform and cellular source of
ApoE [67,79].
In addition to ApoE, other apolipoproteins, such as
ApoA-IV, were also found to regulate Aβ metabolism.
Genetic ablation of ApoA-IV in an AD mouse model
accelerates Aβ deposition, neuron loss and cognitive
impairment [80].
Neprilysin/insulin-degrading enzyme
While familial early-onset AD is associated with
increased Aβ production, defective Aβ degradation may
be involved in late-onset AD (LOAD), which constitutes
approximately 90% of all AD cases [81]. Many enzymes
including, but not limited to, neprilysin (NEP) and
insulin-degrading enzyme (IDE) have been implicated
for a role in degrading Aβ [82]. NEP and IDE are
reduced in AD, and increasing evidence indicates an in-
volvement of them in the imbalance of Aβ production
and clearance relating to AD pathology.
Neprilysin (NEP)
NEP is a 90 ~ 110 kDa plasma membrane glycoprotein
of the neutral zinc metalloendopeptidase family that
degrades enkephalins, endothelins, and Aβ peptides [82].
Particularly, NEP is the major enzyme to degrade soluble
extracellular Aβ in the brain. Recent studies demon-
strated that NEP levels decline in an age-dependent
manner and inversely correlate with levels of insoluble
Aβ in the temporal and frontal cortex of AD and normal
brain [83,84]. NEP expression or activities are decreased
significantly in AD brain [85,86]. The finding that pos-
session of ApoE4 was related to obvious reduction in
NEP levels [85] suggests that down-regulation of NEP
might be implicated in AD pathogenesis.
The transcription of NEP has been demonstrated to be
regulated by AICD which is released during the Aβ gen-
eration [14]. There is a physiological negative feedback
in vivo that keeps Aβ homeostasis, in which Aβ produc-
tion could lead to translocation of AICD to nucleus and
transactivation of NEP. NEP therefore has a role in gov-
erning the balance between Aβ production and degrad-
ation. If such a balance is disrupted, Aβ would come to
be oligomerized and lead to formation of the fibrillar Aβ
protein (fAβ). The resulting fAβ can inhibit the proteo-
lytic activities of the proteases by binding to NEP and
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that accelerates amyloid deposition. Indeed, studies on
transgenic mice of AD have shown that NEP-mediated
degradation of Aβ plays a key role in AD neurodegen-
eration and serves as a novel therapeutic approach to
AD [88]. These findings also suggest that AD pathogen-
esis might result from deficits in Aβ clearance. On the
other hand, however, recent observations in drosophila
demonstrated that NEP overespression could result in
the inhibition of CREB-mediated transcription, age-
dependent axon degeneration and shortened lifespan
[89]. Studies on crossing hAPP transgenic mice and NEP
transgenic mice also showed that, although NEP overex-
pression inhibits plaque formation, it fails to reduce
pathogenic Aβ oligomers and improve the impaired
learning and memory function [90].
Insulin-degrading enzyme (IDE)
IDE is an 110 kDa zinc metalloendopeptidase that highly
expresses in the liver, testis, muscle and brain [82]. The
enzyme has been implicated in the pathogenesis of AD
and type II diabetes due to its capabilities in degrading
Aβ, AICD [91,92], amylin, insulin and insulin-like
growth factors [82]. IDE gene is located in chromosome
10 that is highly associated with later-onset AD (LOAD)
[93]. Some genetic variants of IDE have also been
strongly implicated in LOAD [94,95]. IDE mRNA and
protein levels are markedly decreased in hippocampus of
AD patients with ApoE E4 allele, the genotyping known
as a high risk factor for LOAD [96]. Membrane-bound
IDE levels and its activity are significantly decreased in
subjects with mild cognitive impairment (MCI) and ap-
pear to decrease continuously during the conversion
from MCI to AD [97]. IDE activity is reduced in affected
versus unaffected subjects of three chromosome 10-
linked AD pedigrees, although no significant difference
of IDE expression has been observed [98]. However, re-
cent studies on transgenic AD mouse models showed
that cortical IDE mRNA and protein levels are elevated
in parallel with Aβ40 and Aβ42 generation [99]. In
transgenic tg2576 mice, IDE expression is increased with
age and is located around amyloid plaque as a result of
Aβ-induced inflammation [100]. This phenomena is
similar to the observation that IDE is immunopositive in
senile plaques in human AD brain [101]. Studies on
triple-transgenic mice (hAPPswe/PS1 M146V/hTau
P301L) showed that the expression of IDE was regulated
by 17beta-estrodiol via an ERbeta/PI3K pathway [102].
Unlike NEP that hydrolyzes both monomeric and oligo-
meric Aβ, IDE is found to degrade only soluble mono-
meric Aβ [103]. A recent study by Llovera et al
demonstrated that the catalytic domain of IDE could
form a stable complex with Aβ, which might disrupt Aβ
clearance and facilitate AD neurodegeneration [104].There have been also studies showing that IDE can
cleave C-terminal domain of human acetylcholinesterase
(hAChE) and trigger its conformational conversion from
α to β-structure, which acts as the seed of Aβ fibrils and
enhances the rate of amyloid elongation [105]. This sug-
gests an important role of IDE digestion of C-terminal
domain of hAChE in amyloidogenic pathogenesis of AD.
IDE plays essential role in insulin homeostasis, impli-
cating a close relationship between AD and type II dia-
betes (DM2). A large body of evidence has indicated that
cognitive capacity is often impaired in patients with dia-
betes [106] while insulin resistance is a high risk factor
of AD [107]. IDE knockout mice exhibit hallmarks of
both AD and DM2 [92]. Diet-induced insulin resistance
leads to increased γ-secretase activity and decreased IDE
activity, resulting in elevated Aβ40 and Aβ42 levels in
the brain of Tg2576 mice [108]. Further exploration of
the underlying mechanism has shown that defective in-
sulin receptor signaling may lead to up-regulation of Aβ
generation. Insulin resistance induced by intake of
sucrose-sweetened water or a safflower oil-enriched diet
exacerbates the AD pathology in transgenic AD animal
models [71,109].
Aβ and neurodegeneration
Although it has been widely accepted that Aβ plays a
central role in the onset and progression of AD path-
ology, it remains unclear whether soluble or insoluble
Aβ located in extracellular or intracellular is the culprit
to impaired neuronal function and memory. Meanwhile,
much progress based on neurotoxic lesion, pharmaco-
logical, genetic, and neurophysiological studies in recent
years has led to identification of many new physiological
and biological alterations, such as mitochondrial dys-
function, oxidative stress, synaptic transmission, axonal
trafficking and membrane disruption, that are respon-
sible for the functions of Aβ with significant implications
in developing AD [110,111]. In the following sub-sec-
tions, we selectively review the present research status in
characterization of neurotoxic form of Aβ, and in the
pathological functions of Aβ in synaptic dysfunction and
neuronal inflammation.
Aβ: soluble or insoluble, extracellular or intracellular,
which one is neurotoxic form to AD?
In the last two decades, Aβ hypothesis has been the
focus of AD researches. According to the hypothesis, de-
position of Aβ peptide is the primary cause of driving
AD degeneration and all of the other pathological fea-
tures including intracellular neurofibrillary tangles
(NFT) and neuron loss are the downstream events of
the amyloid cascade [40]. The hypothesis, however, has
been challenged in recent years [112]. Appearance of
large “cotton wool” plaques resulting from PS1
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some special symptoms such as spastic paraparesis ra-
ther than early-onset AD [113]. Decreased dendritic
spine density, impaired synaptic plasticity, and cognitive
dysfunction occur long before amyloid depositions that
appear at 18 months in Tg2576 mice [114]. Hippocam-
pal neuron loss in AD mouse models has been observed
both at the site of amyloid aggregation and in areas dis-
tant from plaques [115].
The classical view is that Aβ is deposited extracellu-
larly, however, emerging evidence from transgenic mice
and human patients has indicated that this peptide can
also be accumulated intraneuronally that contributes to
AD pathogenesis [116]. A PS1 mutated transgenic
mouse model with intracellular Aβ accumulation but
without amyloid plaques exhibits AD-like neurodegen-
eration [117]. Results from the triple-transgenic AD
mouse model (hAPPswe/PS1 M146V/hTau P301L)
showed that impaired synaptic plasticity and cognitive
dysfunction occur prior to the apparent plaques, and are
correlated with the accumulation of intraneuronal Aβ
in hippocampus and amygdale [118,119]. Intracellular
Aβ has been found to accumulate before the generation
of amyloid plaques in many other AD mouse models
[120-124] and in human AD [20,21,125]. As mentioned
above, overexpression of FAD-linked mutant APP alone
could induce the apoptosis of olfactory sensory
neuron and this neurodegeneration is reversible,
suggesting that amyloid plaques are not necessary for
AD neurodegeneration [23].
Evidence has also emerged that the soluble Aβ, but
not amyloid plaques, initiates pathological cascade. Aβ
dimmers derived from untreated human cerebrospinal
fluid (CSF) suppress hippocampal synaptic plasticity
in vivo [126]. Neuron exposure to prefibrillar Aβ can
cause tau-dependent microtubule disassembly [127]. Aβ
oligomers have been observed to disrupt calcium signal-
ing [128], affect the function of NMDA receptor
[129,130], and induce oxidative stress [131] and mito-
chondrial dysfunction [132]. Furthermore, in vitro stud-
ies have demonstrated that β-sheet intermediate (Iβ) of
Aβ prior to fibril formation is more toxic than the fibrils
[133]. It has also been shown that soluble Aβ oligomers
induce reduction in postsynaptic receptors and disrup-
tions of synaptic morphology in cultured hippocampal
neurons [134,135]. Notably, intracerebroventricular in-
jection of AD brain-derived extracts containing soluble
Aβ could lead to obvious inhibition of hippocampal LTP
in rats, supporting the role of SDS-stable Aβ dimer in
mediating synaptic plasticity disruption [136].
Pyroglutamate-amyloid- β (pE3- Aβ), an N-terminal
truncated Aβ species, has recently been found in Aβ
deposits specific to AD brain but absent in normal
aging. Transgenic mice expressing this kind of truncatedAβ showed progressive neurodegeneration including
neuron loss, impaired LTP, microglia activation and
astrocytosis [137]. A signal transduction pathway of sol-
uble Aβ oligomer has recently been delineated, in which
oligomeric Aβ activates Fyn kinase by binding to cellular
prion protein (PrPc) and results in the phosphorylation
of NR2B subunit of NMDA receptor, and eventually
leads to dendritic spine loss and altered synaptic func-
tion [138].
In contrast to the observations mentioned above,
Lesne et al identified the extracellular accumulation of a
soluble 56-kDa Aβ assembly (termed Aβ*56) composed
of 12 Aβ peptides that contributes to the memory im-
pairment in Tg2576 mice [139]. This finding has been
supported by others using transgenic mice with
increased formation of amyloid plaques but reduced
Aβ*56 levels [140]. Taken together, although increasing
data have been accumulated that strongly suggest the
soluble Aβ and intracellular Aβ to be more suspicious in
underlying AD pathogenesis, the involvement of extra-
cellular Aβ in pathologies of the disease is still not
neglectable.
Other pathological functions of Aβ
Aβ and synaptic dysfunction
Aβ has long been shown to affect excitatory synaptic
neurotransmission [13] and hippocampal synaptic plasti-
city [110,126,141]. Aβ oligomers are able to bind specif-
ically to excitatory pyramidal neurons and affect their
synaptic structure, composition and density and the
membrane expression of NMDA receptor [135]. Similar
observations on rat hippocampal slices have also shown
that Aβ oligomers induce loss of hippocampal synapses
and spines in a NMDA receptor-dependent manner
[130]. Aβ exhibits a specific inhibitory role in a pre-
synaptic P/Q calcium current, which is required for syn-
aptic plasticity [128]. Aβ also plays an important role in
activity-dependent presynaptic vesicle release [142].
Moreover, Aβ can induce neuronal network dysfunction
including abnormal induction of excitatory neuronal ac-
tivity and compensatory inhibitory circuits [143]. The
abnormalities of synapse and neuronal network resulting
from Aβ might be the physiological basis of cognitive
decline in AD animal models and patients.
Aβ and inflammation
Microglia is rapidly recruited around amyloid plaques
after its appearance [144]. Aβ can trigger the transloca-
tion of microglia from bone marrow to the sites around
amyloid plaques [145]. Aβ up-regulates P38 MAPK or
p44/42 MAPK signaling, which may lead to microglia
activation with release of cytokines including tumor ne-
crosis factor α (TNF-α) and interleukin-1 β (IL1-β)
[146]. The microglia around plaques maintains the
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blockade and genetic knock-out of TNF-α or iNOS
down-regulate Aβ-induced cognitive dysfunction in AD
mouse model, revealing that TNF-α and iNOS are key
mediator of Aβ neurotoxicity [148]. Genetic disruption
of transforming growth factor β (TGF-β) signaling miti-
gates Aβ levels and amyloid plaques, and partially res-
cues the cognitive abnormality in Tg2576 mice [149].
However, the roles of TGF-β signaling are in a debate.
Tesseur I et al showed that deficiency in TGF-β signal-
ing promotes Aβ accumulation and neuronal degener-
ation [150]. Accumulating evidence also suggests that
functional loss of TGF-β signaling may contribute to
Aβ-induced neurodegeneration and tau pathology, indi-
cating a neuroprotective role of this pathway [151].
Conclusion
AD is a complex neurodegenerative disease involving
the interactions among various potential biological and
environmental factors. Among them, abnormal pro-
cesses of Aβ production, degradation and deposition
have been strongly implicated in the underlying neuro-
pathology and neuropathogenesis of familial earlier-
onset and sporadic later-onset forms of AD. Genes
involved in these processes, including APP, BACE1, PS1/2,
ApoE, NEP, IDE and so on, play important roles in
AD initiation and progression. Further dissection with
depth and breadth of genetic influences may help de-
fining the precise mechanisms involved in the disease
pathogenesis, and eventually leading to development
of new arrays of therapeutics with symptomatic
effects or disease-modifying potential.
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